Abstract
This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and platelet transfusion therapy are covered elsewhere in this volume
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goodnight SH. Bleeding and intravascular clotting in malignancy: a review. Ann NY Acad Sci. 1974;230:271.
Baker WG, Bang NU, Nachman RL, Raafat F, Horowitz H. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. Ann Intern Med. 1964;61:116.
Leavy RA, Kahn SG, Brodsky I. Disseminated intravascular coagulation – a complication of chemotherapy in acute myelomonocytic leukemia. Cancer. 1970;26:142.
Shaw MT. The distinctive features of acute monocytic leukemia. Am J Hematol. 1978;4:97.
Straus DJ, Mertelsmann R, Koziner B, de Harven SE, Arlin ZA, Kempin S, Broxmeyer H, Moore MA, Menendez-Botet CJ, Gee TS, Clarkson BD. The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine (Baltimore). 1980;59:409.
Tobelem G, Jacquillat C, Chastang C, Auclerc M, Lechevallier T, Weil M, Daniel MT, Flandrin G, Harrousseau JL, Schaison G, Boiron M, Bernard J. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood. 1980;55:71.
Speiser W, Pabinger-Fasching I, Kyrle PA, Kaptiotis S, Kottas-Heldenberg A, Bettelheim P, Lechner K. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut. 1990;61:298–302.
Jourdan E, Dombret H, Glaisner S, Miclea JM, Castaigne S, Degos L. Unexpected high incidence of intracranial subdural haematoma during intensive chemotherapy for acute myeloid leukaemia with a monoblastic component. Br J Haematol. 1995;89:527–30.
Cuttner J, Conjalka MS, Reilly M, Goldberg J, Resiman A, Meyer RJ, Holland JF. Association of monocytic leukemia in patients with extreme leukocytosis. Am J Med. 1980;69(4):555–8.
German HJ, Smith JA, Lindenbaum J. Chronic intravascular coagulation associated with chronic myelocytic leukemia. Use of heparin in connection with a surgical procedure. Am J Med. 1976;61:547.
Gingrich RD, Burns CP. Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer. 1979;44:2249.
Whittaker JA, Khurshid M. Hypofibrinogenaemia as a cause of bleeding in chronic myeloid leukaemia. Br Med J. 1975;1:495.
Hirsh J, Buchanan JG, De Gruchy GC, Baikie AG. Hypofibrinogenaemia without increased fibrinolysis in leukaemia. Lancet. 1967;1:418.
Champion LAA, Luddy RE, Schwartz AD. Disseminated intravascular coagulation in childhood acute lymphocytic leukemia with poor prognostic features. Cancer. 1978;41:1642.
Edson JR, Krivit W, White J, Sharp HL. Intravascular coagulation in acute stem cell leukemia successfully treated with heparin. J Pediatr. 1967;71:342.
French AJ, Lilleyman JS. Bleeding tendency of T-cell lymphoblastic leukaemia. Lancet. 1979;2(8140):469–70.
Tornebohm E, Egberg N, Sablica H, Wallin R, Lockner D, Paul C. Elastase activity in leukaemic cells and plasma in patients with acute leukaemia. Eur J Haematol. 1992;49:98–104.
Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Strauss D, Gansbacher B, Filippa D. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79:1305–10.
Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood. 1981;57:518.
Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M, Perutelli P, Crescenzio N, Santora N, Marchetti M, De Mattia D, Falanga A. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol. 2010;85(5):325–30.
Cozzolino F, Torcia M, Miliani A, Carossino AM, Giordani R, Cinotti S, Filimberti E, Saccardi R, Bernabei P, Guidi G, Di Gugliemo R, Pistoria V, Ferrarini M, Nawroth PP, Stern P. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med. 1988;84:240–50.
Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy [Review] [34 refs]. Blood. 1982;60:284–7.
Rocha E, Paramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management [Review] [194 refs]. Haematologica. 1998;83:1024–37.
Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36(1):41–9.
de Jonge E, Levi M, Stoutenbeek CP, Van Deventer SJH. Current drug treatment strategies for disseminated intravascular coagulation. Drugs. 1998;55:767–77.
Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy [see comments]. Ann Int Med. 1993;119:104–9.
Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy – laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782–98.
Hasegawa DK, Bennett AJ, Coccia PF, Ramsay NK, Nesbit ME, Krivit W, Edson JR. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood. 1980;56:585.
Rodeghiero F, Barbui T, Battista R, Chisesi T, Rigoni G, Dini E. Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukemia. Thromb Haemost. 1980;43:6.
Wilson EL, Jacobs P, Dowdle EB. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood. 1983;61:568.
Cowan DH, Graham RC, Baunach D. The platelet defect in leukemia. Platelet ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest. 1975;56:188–200.
Maldonado JE, Pierre RV. The platelets in preleukemia and myelomonocytic leukemia. Ultrastructural cytochemistry and cytogenetics. Mayo Clin Proc. 1975;50:573–87.
Leinoe EB, Hoffmann MH, Kjaersgaard E. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function. Br J Haematol. 2005;128(4):526–32.
Van Der Weyden MB, Clancy RL, Howard MA, Firkin BG. Qualitative platelet defects with reduced life-span in acute leukaemia. Aust N Z J Med. 1972;4:339–45.
Cowan DH, Haut MJ. Platelet function in acute leukemia. J Lab Clin Med. 1972;79:893–905.
Ramos OF, Moron EC, De Castro Arenas R. Platelet function abnormalities in acute leukemia. Haematologia (Budap). 1981;14:383–91.
White JG, Gerrard JM. Ultrastructural textures of abnormal blood platelets: a review. Am J Pathol. 1976;63:590.
Meschengieser S, Blanco A, Woods A, Maugeri N, Fernandez J, Dupont J, Lazzari MA. Intraplatelet levels of vWF: Ag and fibrinogen in myeloproliferative disorders. Thromb Res. 1987;48:311–9.
Raman BKS, Van Slyck EJ, Riddle J, Sawdyk MA, Abraham JP, Saeed SM. Platelet function and structure in myeloproliferative disease, myelodysplastic syndrome, and secondary thrombocytosis. Am J Clin Pathol. 1989;91:647–55.
Lintula R, Rasi V, Ikkala E, Borgstrom GH, Vuopio P. Platelet function in preleukaemia. Scand J Haematol. 1981;26:65–71.
Avvisati G, Buller HR, ten Cate JW, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;ii:122–4.
Bain BJ, Catovsky D, O’Brien M, Prentice HG, Lawlor E, Kumaran TO, McCann SR, Matutes E, Galton DA. Megakaryoblastic leukemia presenting as acute myelofibrosis – a study of four cases with the platelet-peroxidase reaction. Blood. 1981;58:206.
Pogliani EM, Colombi M, Cofrancesco E, Salvatore M, Fowst C. Platelet dysfunction in acute megakaryoblastic leukemia. Acta Haematol (Basel). 1989;81:1–4.
Bevan D, Rose M, Greaves M. Leukaemia of platelet precursers: diverse features in four cases. Br J Haematol. 1982;51:147–64.
Franchini M, Dario Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost. 2010;36(4):388–403.
Manoharan A, Brighton T, Gemmell R, Lopez K, Moran S, Kyle P. Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study. Int J Hematol. 2002;76(3):272–8.
Kerkhofs H, Hagemeijer A, Leeksma CHW, Abels J, denOttolander GJ, Somers R, Gerrits WBJ, Langenhuiÿen MMAC, von dem borne AEGK, van Hemel JO, Geraedts JPM. The 5q – chromosome abnormality in haematologic disorders: a collaborative study of 34 cases from the Netherlands. Br J Haematol. 1982;52:365–81.
Mahmood T, Robinson WA, Hamstra RD, Wallner SF. Macrocytic anemia, thrombocytosis and nonlobulated megakaryocytes. The 5q− syndrome, a distinct entity. Am J Med. 1979;66:946–50.
Bernstein R, Pinto MR, Behr A, Mendelow B. Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a “new” inversion anomaly and a further case of homologous translocation. Blood. 1982;60:613–7.
Cortelazzo S, Viero P, D’Emilio A, DeGaetano G, Barbui T. Platelet dysfunction in splenectomized patients with hairy cell leukemia. Eur J Cancer Clin Oncol. 1986;22:935–7.
Sweet DL, Golumb HM. Correction of platelet defect after splenectomy in hairy cell leukemia. JAMA. 1979;241:1684.
Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP. Platelet function in hairy-cell leukaemia. J Clin Pathol. 1979;32:814–21.
Rosove MH, Naeim F, Harwig S, Zighelboim J. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood. 1980;55:903–6.
Wang YL, Vandris K, Jones A, Cross NCP, Christos P, Adriano F, Silver RT. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008;22(6):1289.
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459–68.
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.
Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia [Review] [51 refs]. Semin Oncol. 1995;22:327–33.
Gunz FW. Hemorrhagic thrombocythemia: a critical review. Blood. 1960;15:706.
Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549–56.
Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, Boiron M. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986;58:2440–7.
Lemoine F, Najman A, Baillou C, Stachowiak J, Boffa G, Aegerter P, Douay L, Laporte JP, Gorin NC, Duhamel G. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986;68:996–1002.
Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Hematology. 1991;63(2):101–6.
Schafer AI. Essential Thrombocythemia. In: Coller BS, editor. Progress in hemostasis and thrombosis. Philadelphia: W.B. Saunders; 1991. p. 69–96.
Buss DH, Cashell AW, O’Connor ML, Richards II F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247–53.
Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.
Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78(1):617.
Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135–7.
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.
Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol. 1983;19:1593–9.
Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Binda T, Varet B, Rueff B, Benhamou JP. Myeloproliferative disorders in portal vein thrombosis in adults. Gastroenterology. 1988;94:1063–9.
Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67:285–91.
Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–62.
Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–43.
Chievitz E, Thede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513–23.
Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10–5.
Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132–9.
Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia [see comments]. Ann Intern Med. 1995;123:656–64.
Petti MC, Spadea A, Avvisati G, Spadea T, Latagliata R, Montefusco E, Cosenza M, Malagnino F. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991). Leukemia. 1998;12:869–74.
Passamonti F. New and old prognostic factors in polycythemia vera. Curr Hematol Malig Rep. 2009;4(1):19–24.
Landolfi R, Di GL, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22(11):2020–8.
Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, Rodeghiero F, Delaini F, Rambaldi A, Barbui T. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116(7):1051–5.
Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66.
Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, De Vivo A, Salmi F, Lucchesi A, Baccarani M, Vianelli N. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84(4):215–20.
Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, Berretta S, Schinocca L, Quintini G, Abbadessa V, Di Raimondo F, Siragusa S. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol. 2009;88(10):967–71.
Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, Leone G, Marfisi R, Porreca E, Ruggeri M, Rutjes AW, Tognoni G, Vannucchi AM, Marchioli R, European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249–59.
Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente EA, Leporrier M, Rueff B, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. Ann Intern Med. 1985;103:329–34.
Reid CDL, Fidler J, Kirk A. Endogenous erythroid clones (EEC) in polycythaemia and their relationship to diagnosis and the response to treatment. Br J Haematol. 1988;68:395–400.
Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Binda T, Varet B, Rueff B, Benhamou JP. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063–9.
Lengfelder E, Hochhaus A, Kronawitter U, Höche D, Queisser W, Jahn-Eder M, Burkhardt R, Reiter A, Ansari H, Hehlmann R. Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol. 1997;100:15–23.
Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997;56:168–72.
Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409–17.
De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94(5):733–7.
De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol. 2010;89(2):141–6.
Girodon F, Dutrillaux F, Broseus J, Mounier M, Goussot V, Bardonnaud P, Chretien ML, Maynadie M. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010;24(4):900–3.
Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009;115(24):5740–5.
Michiels JJ, Abels J, Steketee J, VanVliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466–71.
Michiels JJ, Ten Kate FJW. Erythromelalgia in thrombocythemia of various myeloproliferative disorders. Am J Hematol. 1992;39:131–6.
Singh AK, Wetherley-Mein G. Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol. 1977;36:553.
Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64:1–12.
Gilbert HS. The spectrum of myeloproliferative disorders. Med Clin North Am. 1973;57:355.
Silverstein MN. Primary or hemorrhagic thrombocythemia. Arch Intern Med. 1968;122:18.
Spaet TH, Bauer S, Melamed S. Hemorrhagic thrombocythemia: a blood coagulation disorder. Arch Intern Med. 1956;98:377.
Zucker S, Mielke CH. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications. J Lab Clin Med. 1972;80:385–94.
Preston FE, Emmanuel IG, Winfield DA, Malia RG. Essential thrombocythaemia and peripheral gangrene. Br Med J. 1974;3:548.
Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HHDM. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology. 1993;43:1107–10.
Nimer SD. Essential thrombocythemia: another “heterogeneous disease” better understood? [letter; comment] [Review] [12 refs]. Blood. 1999;93:415–6.
Andreasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. Blood. 2003;101(2):783.
Chiusolo P, La Barbera EO, Laurenti L, Piccirillo N, Sora F, Giordano G, Urbano R, Mazzucconi MC, De Stefano V, Leone G, Sica S. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. Exp Hematol. 2001;29(6):670–6.
Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417–24.
Cunietti E, Gandini R, Mascaro G, Ferrari M, Pappalepore V, Scapellato L. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. Scand J Haematol. 1981;26:339–44.
Givelber AD. Platelet function in patients with high platelet counts. Ann Intern Med. 1975;82:506.
Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer. 1988;61:2487–96.
Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med. 1984;103:894–904.
Waddell CC, Brown JA, Repinecz YA. Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med. 1981;105:432–5.
Walsh PN, Murphy S, Barry WE. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb Haemost. 1977;38:1085–96.
Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med. 1978;88:7.
Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost. 1984;52:292–6.
Boughton BJ, Allington MJ, King A. Platelet and plasma beta thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol. 1978;40:125–32.
Cortelazzo S, Barbui T, Bassan R. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. Thromb Haemost. 1980;44:127.
Castaldi PA, Berndt MC, Booth W, Gregory C, Bull H, Greaves M. Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res. 1982;27:601–9.
Eche N, Sie P, Caranobe C, Nouvel C, Pris J, Boneu B. Platelets in myeloproliferative disorders. III: Glycoprotein profile in relation to platelet function and platelet density. Scand J Haematol. 1981;26:123–9.
Moore A, Nachman RL. Platelet Fc receptor: increased expression in myeloproliferative disease. J Clin Invest. 1981;67:1064–71.
Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol. 1982;51:469–77.
Keenan JP, Wharton J, Shepherd AJN, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. Br J Haematol. 1977;35:275–83.
Schafer AI. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med. 1982;306:381–6.
Stenke L, Edenius C, Samuelsson J, Lindgren JA. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood. 1991;78:2989–95.
Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemost. 1979;42:794–6.
Woodruff RK, Bell WR, Castaldi PA, Streatfield K, Penington DG. Essential thrombocythaemia. Haemostasis. 1980;9:105.
Baker RI, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol. 1988;40:267–72.
Wehmeier A, Fricke S, Scharf RE, Schneider W. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur J Haematol. 1990;45:191–7.
Cardamone JM, Edson JR, McArthur JR, Jacob HS. Abnormalities of platelet function in the myeloproliferative disorders. JAMA. 1972;221:270–3.
Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986;68:1213–7.
Raman BKS, Sawdyk M, Saeed SM. Essential thrombocythemia with acquired von Willebrand’s disease. Am J Clin Pathol. 1987;88:102–6.
Mohri H, Ohkubo T. Acquired von Willebrand’s syndrome due to an inhibitor of IgG specific for von Willebrand’s factor in polycythemia rubra vera. Acta Haematol (Basel). 1987;78:258–64.
Lee LH, Baglin T. Altered platelet phospholipid-dependent thrombin generation in thrombocytopenia and thrombocytosis. Br J Haematol. 1995;89:131–6.
Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Liver. 1999;105:618–25.
Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.
Burstein SA, Malpass TW, Yee E, Kadin M, Brigden M, Adamson JW, Harker LA. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol. 1984;57:383–92.
Berild D, Hasselbalch H, Knudsen J. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders. Scand J Clin Lab Invest. 1987;47:497–501.
Katoh O, Kimura A, Kuramoto A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol. 1988;27:276–80.
Baglin TP, Price SM, Boughton BJ. A reversible defect of platelet PDGF content in myeloproliferative disorders. Br J Haematol. 1988;69:483–6.
Shamasunder HK, Gregory SA, Knospe WH. Uracil mustard in the treatment of thrombocytosis. JAMA. 1980;244:1454–5.
Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102–8.
Gisslinger H, Rodeghiero F, Ruggeri M, Heis-Vahidi Fard N, Mannhalter C, Papagiannopoulos M, Rintelen C, Lalouschek W, Knöbl P, Lechner K, Pabinger I. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Liver. 1999;105:551–5.
Faurschou M, Nielsen OJ, Jensen MK, Hasselbalch HC. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders. Am J Hematol. 2000;65:136–40.
Marchetti M, Castoldi E, Spronk HM, van Oerle R, Balducci D, Barbui T, Rosing J, Ten Cate H, Falanga A. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061–8.
Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169–75.
Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143–51.
Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol. 1997;56:5–11.
Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.
Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246–9.
Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, Ayats R, Salvador C, Muntañola A, Bellosillo B, Vicente V, Hernández-Nieto L, Burgaleta C, Xicoy B, Besses C. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–10.
Pagliuca A, Mufti GJ, Janossa-Tahernia M, Eridani S, Westwood NB, Thumpston J, Sawyer B, Sturgess R, Williams R. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis – possible evidence of an occult myeloproliferative state. Quarterly J Med. 1990;281:981–9.
Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113(22):5617–23.
Goldstein R, Clark P, Klintmalm G, Husberg B, Gonwa T, Stone M. Prevention of recurrent thrombosis following liver transplantation for Budd-Chiari syndrome associated with myeloproliferative disorders: treatment with hydroxyurea and aspirin. Transplant Proc. 1991;23:1559–60.
Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver transplantation for the Budd-Chiari syndrome. Ann Surg. 1990;211:43–9.
van Genderen PJJ, Michiels JJ, van Strik R, Lindemans J, Van Vliet HHDM. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 1995;73:210–4.
van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Liver. 1997;97:179–84.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.
Goodnight SH. Antiplatelet therapy with aspirin: from clinical trials to practice. Thromb Haemost. 1995;74:401–5.
Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–6.
Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs. 1994;47:809–22.
Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med. 1992;92:69–76.
Silverstein MN, Petitt RM, Solber LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med. 1988;318:1292–4.
Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863–6.
Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis. 1998;24:9–13.
Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33–45.
Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol. 1994;91:126–9.
Ludwig H, Linkesch W, Gisslinger H, Fritz E, Sinzinger H, Radaszkiewicz T, Chott A, Flener R, Micksche M. Interferon-alpha corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother. 1987;25:266–73.
Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G, Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106(11):2397–405.
Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9):2012–8.
Haogland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc. 1978;53:578.
Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–7.
Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150–4.
Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol. 2011;23(6):609–16.
Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9.
Shpilberg O, Shimon I, Sofer O, Dolitski M, Ben Bassat I. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia. [see comments]. Br J Haematol. 1996;92:491–3.
Wright CA, Tefferi A. A single institutional experience with 43 preganancies in essential thrombocythemia. Eur J Haematol. 2001;66:152–9.
Bangerter M, Guthner C, Beneke H, Hildebrand A, Grunewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000;65:165–9.
Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, Martino B, Scalzulli PR, Latagliata R, Palmieri F, Usala E, Valente D, Valvano MR, Cedrone M, Comitini G, Martinelli V, Cascavilla N, Gugliotta L. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J Hematol. 2009;84(10):636–40.
Tefferi A, Passamonti F. Essential thrombocythemia and pregnancy: observations from recent studies and management recommendations. Am J Hematol. 2009;84(10):629–30.
Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82(5):350–3.
Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010;8(2):411–3.
Bessler M, Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2008;104–10.
Matei D, Brenner B, Marder VJ. Acquired thrombophilic syndromes. Blood Rev. 2001;15:31–48.
Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C, Heudier P, Rochant H, Cahn JY, Gluckman E. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology [see comments]. Lancet. 1996;348:573–7.
Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient [Review] [66 refs]. Haemostasis. 2000;30:103–17.
Gralnick HR, Vail M, McKeown LP, Merryman P, Wilson O, Chu I, Kimball J. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haemotol. 1995;91:697–702.
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8.
Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587–91.
Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126(1):133–8.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.
Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socié G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8.
Zangari M, Elice F, Fink L, Tricot G. Hemostatic dysfunction in paraproteinemias and amyloidosis. Semin Thromb Hemost. 2007;33(4):339–49.
Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009;145(2):151–63.
Nilehn J, Nilsson IM. Coagulation studies in different types of myeloma. Acta Med Scand. 1966;179:194.
Perkins HA, MacKenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood. 1970;35:695–707.
Lackner H, Hunt V, Zucker MB, Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol. 1970;18:625–36.
Coleman M, Vigliano EM, Weksler ME, Nachman RL. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood. 1972;39:210–23.
Davey FR, Gordon GB, Boral LI, Gottlieb AJ. Gamma globulin inhibition of fibrin clot formation. Ann Clin Lab Sci. 1976;6:72–7.
Klingemann HG, Egbring R, Havemann K. Incomplete fibrin formation and highly elevated factor XIII activity in multiple myeloma. Scand J Haematol. 1981;27:253–62.
Jeannette S, Soria C, Samama M, Fine JM, Bousser J. Analysis of fibrin formation abnormality in a case of multiple myeloma. Scan J Haematol. 1975;15:207.
Kaufman PA, Gockerman JP, Greenberg CS. Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. Am J Med. 1989;86:612–6.
Pachter MR, Johnson SA, Neblett TR, Truant JP. Bleeding, platelets, and macroglobulinemia. Am J Clin Pathol. 1959;31:467–82.
Kasturi J, Saraya AK. Platelet functions in dysproteinemia. Acta Haematol (Basel). 1978;59:104–13.
DiMinno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest. 1986;77:157–64.
Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol. 1999;62:99–102.
Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol. 1996;51:319–23.
Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, Landgren O. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–6.
Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991–8.
Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006;47(6):947–55.
Mumford AD, O’Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110:454–60.
Gamba G, Montani N, Anesi E, Palladini G, Capezzera M, Soldavini E, Merlini G. Clotting alterations in primary systemic amyloidosis. Haematologica. 2000;85:289–92.
Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis. N Engl J Med. 1977;297:81–5.
Korsan-Bengtsen K, Hjort PF, Ygge J. Acquired factor X deficiency in a patient with amyloidosis. Thromb Diath Haemorrh. 1962;7:558–66.
Camoriano JK, Greipp PR, Bayer GK, Bowie EJW. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med. 1987;316:1133–5.
Rosenstein ED, Itzkowitz SH, Penziner AS, Cohen JI, Mornaghi RA. Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med. 1983;143:597–9.
Greipp PR, Kyle RA, Bowie EJW. Factor X deficiency in primary amyloidosis. N Engl J Med. 1979;301:1050–1.
Hartley-Brown MA, Sullivan DM, Baz R. State-of-the-art management of complications of myeloma and its treatment. Adv Hematol. 2010;2010:343089.
Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA. 1983;249:1322–4.
Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97:1885–7.
Shigekiyo T, Kosaka M, Shintani Y, Azuma H, Iishi Y, Saito S. Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis. Acta Haematol (Basel). 1989;81:160–5.
Glueck HI, Coots MC, Benson M, Dwulet FE, Hurtubise PE. A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization. J Lab Clin Med. 1989;113:269–77.
Leibman H, Chinowsky M, Valdin J, Kenoyer G, Feinstein D. Increased fibrinolysis and amyloidosis. Arch Intern Med. 1983;143:678–82.
Meyer K, Williams EC. Fibrinolysis and acquired alpha-2 plasmin inhibitor deficiency in amyloidosis. Am J Med. 1985;79:394–6.
Sane DC, Pizzo SV, Greenberg CS. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Am J Hematol. 1989;31:53–7.
Chang JC, Kane KK. Pathologic hyperfibrinolysis associated with amyloidosis: clinical response to epsilon amino caproic acid. Am J Clin Pathol. 1984;81:382–7.
Takahashi H, Kolke T, Yoshida N, Kitahara O, Hanano M, Shibata A, Aoki N. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha-2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol. 1986;23:153–66.
Hassidim K, McMillan R, Conjalka MS, Morrison J. Immune thrombocytopenic purpura in Hodgkin Disease. Am J Hematol. 1979;6:149–53.
Berkman AW, Woog JJ, Kickler TS, Ettinger DS. Serial determinations of antiplatelet antibodies in a patient with Hodgkin’s Disease and autoimmune thrombocytopenia. Cancer. 1983;51:2057–60.
Carey RW, McGinnis A, Jacobson BM, Carvalho A. Idiopathic thrombocytopenic purpura complicating chronic lymphocytic leukemia. Arch Intern Med. 1976;136:62–6.
Cohen JR. Idiopathic thrombocytopenic purpura in Hodgkin’s Disease. Cancer. 1978;41:743–6.
Fink K, Al-Mondhiry H. Idiopathic thrombocytopenic purpura in lymphoma. Cancer. 1976;37:1999–2004.
Hamilton PJ, Dawson AA. Thrombocytopenic purpura as the sole manifestation of a recurrence of Hodgkin’s disease. J Clin Pathol. 1973;26:70–2.
Hussein KK, Shaw MT, Oleinick SR. Autoimmune thrombocytopenia and peripheral neuropathy heralding Hodgkin’s Disease. South Med J. 1975;68:1414–6.
Julia A, Miller SP. Idiopathic thrombocytopenic purpura in Hodgkin’s disease after splenectomy. Am J Hematol. 1976;1:115–20.
Kaden BR, Rosse WF, Hauch TW. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 1979;53:545–51.
Kedar A, Khan AB, Mattern JQA, Fisher J, Thomas PRM, Freeman AI. Autoimmune disorders complicating adolescent Hodgkin’s Disease. Cancer. 1979;44:112–6.
Khilanani P, Al-Sarraf M. The association of autoimmune thrombocytopenia and Hodgkin’s Disease. Oncology. 1973;28:238–45.
Kirshner JJ, Zamkoff KW, Gottlieb AJ. Idiopathic thrombocytopenic purpura and Hodgkin’s disease: report of two cases and a review of the literature. Am J Med Sci. 1980;280:21–8.
Rudders RA, Aisenberg AC, Schiller AL. Hodgkin’s disease representing as “idiopathic” thrombocytopenic purpura. Cancer. 1972;30:220–30.
Waddell CC, Cimo PL. Idiopathic thrombocytopenic purpura occurring in Hodgkin Disease after splenectomy: report of two cases and review of the literature. Am J Hematol. 1979;7:381–7.
Weitzman S, Dvilansky A, Yanai I. Thrombocytopenic purpura as the sole manifestation of recurrence in Hodgkin’s Disease. Acta Haematol (Basel). 1977;58:129–33.
Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003;74(1):1–8.
Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–8.
Aghai E, Quitt M, Lurie M, Antal S, Cohen L, Bitterman H, Froom P. Primary hepatic lymphoma presenting as symptomatic immune thrombocytopenic purpura. Cancer. 1987;60:2308–11.
Veenhoven WA, Thomas-Van Der Schans GS, Nieweg HO. Monoclonal immunoglobulins with affinity for platelets and their relationship to malignant lymphoma. Cancer. 1982;49:40–2.
Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):230–9.
Kempin S. Late hematologic complications after treatment of Hodgkin’s disease. In: Lacher MJ, Redman JR, editors. Hodgkin’s disease: the consequences of survival. Philadelphia: Lea & Febiger; 1990. p. 63.
Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann’s thrombasthenia associated with Hodgkin’s lymphoma: a case report and review of the literature. Cancer. 1998;82:1764–8.
Karpatkin S. Autoimmune thrombocytopenic purpura. Blood. 1980;56:329–43.
McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;304:1135–47.
Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999–1004.
Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4):952–7.
George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J MEd. 1994;331:1207–11.
Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–8.
Parks JS, Kaduck-Sawyer J, Bullock BC, Rudel LL. Effect of dietary fish oil on coronary artery and aortic atherosclerosis in African green monkeys. Arteriosclerosis. 1990;10:1102–12.
Proctor SJ, Jackson G, Carey P, Stark A, Finney R, Saunders P, Summerfield G, Maharaj D, Youart A. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha-2b interferon. Blood. 1989;74:1894–7.
Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330:1560–4.
Zettervall O, Nilsson IM. Acquired von Willebrand’s disease caused by a monoclonal antibody. Acta Med Scand. 1978;204:521.
Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997;103(6):536–40.
Jonge Poerink-Stockschlader AB, Dekker I, Risseeuw-Appel IM, Hahlen K. Acquired Von Willebrand disease in children with a Wilms’ tumor. Med Pediatr Oncol. 1996;26(4):238–43.
Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22(1):62–5.
Eikenboom JC, Tjernberg P, Van Marion V, Heering KJ. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options. Am J Hematol. 2007;82(1):55–8.
Wautier JL, Levy-Toledano S, Caen JP. Acquired von Willebrand’s syndrome and thrombopathy in a patient with chronic lymphocytic leukaemia. Scand J Haematol. 1976;16:128–34.
Veyradier A, Jenkins CS, Fressinaud E, Meyer D. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost. 2000;84:175–82.
Federici AB. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6(4):565–8.
Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol. 2007;82(5):368–75.
Michiels JJ, Budde U, van der Planken M, Van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Baillieres Best Pract Clin Haematol. 2001;14(2):401–36.
Facon T, Caron C, Courtin P, Wurtz A, Deghaye M, Bauters F, Mazurier C, Goudemand J. Acquired type II von Willebrand’s disease associated with adrenal cortical carcinoma. Br J Haematol. 1992;80:488–94.
Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand’s disease: an newly defined inhibitor syndrome. Blood. 1976;48:393–405.
Joist JH, Cowan JF, Zimmerman TS. Acquired von Willebrand’s disease. Evidence for a quantitative and qualitative factor VIII disorder. N Engl J Med. 1978;298:988–91.
Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand’s disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol. 1997;96:850–3.
van Genderen PJ, Michiels JJ. Acquired von Willebrand disease [Review] [54 refs]. Baillieres Clin Haematol. 1998;11(2):319–30.
Brody JI, Haidar ME, Rossman RE. A hemorrhagic syndrome in Waldenstrom’s macroglobulinemia secondary to immunoadsorption of factor VIII. N Engl J Med. 1979;300:408–10.
Mohri H, Noguchi T, Kodama F, Itoh A, Ohkubo T. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol. 1987;87:663–8.
Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand’s disease. Transfusion. 1987;27:234–7.
White LA, Chisholm M. Gastro-intestinal bleeding in acquired von Willebrand’s disease: efficacy of high-dose immuno-globulin where substitution treatments failed. Br J Haematol. 1993;84:332–4.
Hanley D, Arkel YS, Lynch J, Kamiyama M. Acquired von Willebrand’s syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin. Am J Hematol. 1994;46:141–6.
Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Investig Drugs. 2000;9(2):347–54.
Delmer A, Horellou MH, Bréchot JM, Prudent J, Potevin F, Lecrubier C, Girard-Longhini C, Samama M, Zittoun R. Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol. 1992;40:151–2.
Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 2001;66:292–4.
Wenz B, Friedman G. Acquired factor VIII inhibitor in a patient with malignant lymphoma. Am J Med Sci. 1974;268:295–9.
Castaldi PA, Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood. 1970;35:370–6.
Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer. 2001;91:636–41.
Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol. 1997;97:219–26.
Bussel JB, Steinherz PG, Miller DR, Hilgartner MW. A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. Am J Hematol. 1984;16:83–90.
Khoory MS, Nesheim ME, Bowie EJW, Mann KG. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest. 1980;65:666–74.
Tefferi A, Nichols WL, Bowie EJW. Circulating heparin-like anticoagulants: report of five consecutive cases and a review. Am J Med. 1990;88:184–8.
Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335.
Sills RH, Nelson DA, Stockman JA. L-asparaginase – induced coagulopathy during therapy of acute lymphocytic leukemia. Med Pediatr Oncol. 1978;4:311–3.
Anderson N, Lokich JJ, Tullis JL. L-asparaginase effect on antithrombin-III levels. Med Pediatr Oncol. 1979;7:335–40.
Barbui T, Finazzi G, Vigano S, Mannucci PM. L-asparaginase lowers protein C antigen. Thromb Haemost. 1984;52:216.
Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr. 1986;108:698–701.
Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol. 1980;8:7–14.
Conrad J, Horellou MH, Van Dreden P, Potevin F, Zittoun R, Samama M. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol. 1985;59:725–7.
Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment. Cancer. 1971;27:1313–20.
Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol. 1987;5:811–7.
Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with l-Asparaginase. Cancer. 1982;50:451.
Pui CH, Jackson CW, Chesney C, Lyles SA, Bowman WP, Abromowitch M, Simone JV. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine. J Clin Oncol. 1983;1:380–5.
Ramsay NKC, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase on plasma coagulation factors in acute lymphoblastic leukemia. Cancer. 1977;40:1398–401.
Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. Hypofibrinogenemia due to L-asparaginase: studies of fibrinogen survival using autologous 131I-fibrinogen. Blood. 1970;35:195–200.
Nowak-Gottl U, Ahlke E, Klosel K, Jurgens H, Boos J. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations. Eur J Pediatr. 1997;156:848–50.
Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96:1709–15.
Groopman J, Ellman L. Acute promyelocytic leukemia. Am J Hematol. 1979;7:395.
Sultan C, Heilmann-Gouault M, Tulliez M. Relationship between blast-cell morphology and occurrence of a syndrome of disseminated intravascular coagulation. Br J Haematol. 1973;24:255.
Pui CH, Jackson CW, Chesney CM, Abildgaard CF. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol. 1987;25:291–8.
Bauer KA, Teitel JM, Rosenberg RD. L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state. Thromb Res. 1983;29:437–42.
Caruso V, Iacoviello L, Di CA, Storti S, Mariani G, de Gaetano G, Donati MB. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–22.
Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, Cherrick I, Desai S, Mahoney D, McCuster P, Wu J, Dahl G, Chait P, de Veber G, Lee KJ, Mikulis D, Ginsberg J, Way C, Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97(2):508–16.
Caruso V, Iacoviello L, Di CA, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5(3):621–3.
Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109(7):2744–50.
Cairo MS, Lazarus K, Gilmore RL, Baehner RL. Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia. J Pediatr. 1980;97:829–33.
Priest JR, Ramsay NKC, Steinherz PG, Tubergen DG, Cairo MS, Sitarz AL, Bishop AJ, White L, Trigg ME, Levitt CJ, Cich JA, Coccia PF. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984–9.
Pui CH, Chesney CM, Bergum PW, Jackson CW, Rapaport SI. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol. 1986;64:283–90.
Steinherz PG, Miller LP, Ghavimi F, Allen JC, Miller DR. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA. 1981;246:2837.
Urban C, Sager WD. Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia. Eur J Pediatr. 1981;137:323.
Gugliotta L, Mazzucconi M-G, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. Eur J Haematol. 1992;49:63–6.
Priest JR, Ramsay NKC, Latchaw RE, Lockman LA, Hasegawa DK, Coates TD, Coccia PF, Edson JR, Nesbit ME, Krivit W. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer. 1980;46:1548–54.
Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93:1595–9.
Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83:840–3.
Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338(8767):597–600.
Stock W, Douer D, Deangelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–53.
Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, Bidlingmaier C, Frühwald MC, Heller C, Schmidt W, Pautard B, Nowak-Göttl U. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115(24):4999–5004.
Quintas-Cardama A, Kantarjian H, Ravandi F, O’Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115(11):2482–90.
Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114(2):261–3.
Antimicrobials and haemostasis. Lancet. 1983;i:510–1
Sattler FR, Weitekamp MR, Sayegh A, Ballard JO. Impaired hemostasis caused by beta-lactam antibiotics. Am J Surg. 1988;155:30–9.
Andrassy K, Weischedel E, Ritz E, Andrassy T. Bleeding in uremic patients after carbenicillin. Thromb Haemost. 1976;36:115–26.
Bang NU, Tessler SS, Heidenreich RO, Marks CA, Mattler LE. Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis. 1982;4:S546–54.
Brown CH, Natelson EA, Bradshaw MW, Williams TW, Alfrey CP. The hemostatic defect produced by carbenicillin. N Engl J Med. 1974;291:265–70.
Cazenave JP, Guccione MA, Packham MA, Mustard JF. Effects of cephalothin and penicillin G on platelet function in vitro. Br J Haematol. 1977;35:135–52.
Haburchak DR, Head DR, Everett ED. Postoperative hemorrhage associated with carbenicillin administration. Am J Surg. 1977;134:630.
Johnson GJ, Rao GHR, White JG. Platelet dysfunction induced by parenteral carbenicillin and ticarcillin. Am J Pathol. 1978;91:85–106.
Natelson EA, Siebert WT, Williams TW, Bradshaw MW. Combined effects of ticarcillin and cefazolin on blood coagulation and platelet function. Am J Med Sci. 1979;278:217–21.
Pakter RL, Russell TR, Mielke CH, West D. Coagulopathy associated with the use of moxalactam. JAMA. 1982;248:1100.
Weitekamp MR, Aber RC. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA. 1983;24:69–71.
Matsubara T, Touchi A, Harauchi T, Takano K, Yoshizaki T. Depression of liver microsomal vitamin K epoxide reductase activity associated with antibiotic-induced coagulopathy. Biochem Pharmacol. 1989;38:2693–701.
Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med. 1986;105:924–31.
Shevchuk YM, Conly JM. Antibiotic-associated hypoprothrombinemia: a reivew of prospective studies, 1966–1988. Rev Infect Dis. 1990;12:1109–26.
Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, Faubion C, Saviteer S, Cohen MS. Prospective comparative trial of short course (four day) and continuous Tobramycin in combination with Cefoperazone or Mezlocillin in febrile, granulocytopenic patients. J Antimicrob Chemother. 1989;24:591–604.
Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115:849–59.
Conly J, Suttie J, Reid E, Loftson J, Ramotar K, Louie T. Dietary deficiency of phylloquinone and reduced serum levels in febrile neutropenic cancer patients. Am J Clin Nutr. 1989;50:109–13.
Brown CH, Natelson EA, Bradshaw MW, Alfrey CP, Williams TW. Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother. 1975;7:652–7.
Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–7.
Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, Baker KR, Aster RH. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356(9):904–10.
Zenon GJ, Cadle RM, Hamill RJ. Vancomycin-induced thrombocytopenia. Arch Intern Med. 1991;151:995–6.
Chan CSP, Tuazon CU, Lessin LS. Amphotericin-B-induced thrombocytopenia. Ann Intern Med. 1982;96:332–3.
Kulpa J, Zaroulis CG, Good RA, Kutti J. Altered platelet function and circulation induced by amphotericin B in leukemic patients after platelet transfusion. Transfusion. 1981;21:74–6.
Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep. 1981;65:677–9.
Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Mryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–7.
Rogers JS, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6:276–81.
Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–9.
Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–9.
Wun T, White RH. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res. 2010;125 Suppl 2:S96–102.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.
Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. Blood. 2011;118(5):1239–47.
Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:437–44.
Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 1996;10(2):485–97.
Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005;31(6):681–90.
Gharpure VS, Devine SM, Holland HK, Geller RB, O’Toole K, Wingard JR. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. Bone Marrow Transplant. 1995;16(5):715–6.
Wu DC, Liu JM, Chen YM, Yang S, Liu SM, Chen LT, Whang-Peng J. Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Jpn J Clin Oncol. 1997;27(2):115–8.
Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP. 2005;6(4):369–74.
Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst. 1997;89:1895–6.
Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85(9):2023–32.
Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N, Billemont B, Deray G. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038–45.
Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002;40(4):E16.
Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher. 2009;24(5):209–14.
Shulman HM, Hinterberger W. Hepatic veno-occlusive disease – liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197–214.
Baron F, Deprez M, Beguin Y. The veno-occlusive disease of the liver [Review] [64 refs]. Haematologica. 1997;82:718–25.
McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51(4):1450–60.
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–67.
Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, Dienes HP, Koerner K, Bunjes D, Arnold R, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83:1998–2004.
Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED. An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology. 1980;79:1178–91.
McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–22.
Jones RJ, Lee KSK, Beschorner WE, Vogel VG, Grochow LB, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83.
Kami M, Mori S, Tanikawa S, Akiyama H, Onozawa Y, Tanaka T, Okamoto R, Maeda Y, Sasaki T, Kaku H, Matsuura Y, Hiruma K, Sakamaki H. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution. Bone Marrow Transplant. 1997;20:397–402.
Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.
Kaufman PA, Jones RB, Greenberg CS, Peters WP. Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Cancer. 1990;66:515–21.
Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81:3458–62.
Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D’Agay MF, Gluckman E. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63:509–19.
Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89:2184–8.
Park YD, Yasui M, Yoshimoto T, Chayama K, Shimono T, Okamura T, Inoue M, Yumura-Yagi K, Kawa-Ha K. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19:915–20.
Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–6.
Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;79:2834–40.
Fogteloo AJ, Smid WM, Kok T, van der Meer J, Van Imhoff GW, Daenen S. Successful treatment of veno-occlusive disease of the liver with urokinase in a patient with non-Hodgkin’s lymphoma. Leukemia. 1993;7:760–3.
Bearman SI, Shuhard MC, Hinds MS, McDonald GB. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood. 1992;80:2458–62.
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–9.
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44.
Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost. 2007;33(4):373–88.
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.
Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16(7):1005–17.
Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34(2):126–33.
Clark RE. Thrombotic microangiopathy following bone marrow transplantation [see comments]. Bone Marrow Transplant. 1994;14(4):495–504.
Fuge R, Bird JM, Fraser A, Hart D, Hunt L, Cornish JM, Goulden N, Oakhill A, Pamphilon DH, Steward CG, Marks DI. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001;113(1):58–64.
Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002;30(11):709–15.
Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs. 2009;69(2):183–98.
Van der Plas RM, Schiphorst ME, Huizinga EG, Hené RJ, Verdonck LF, Sixma JJ, Fijnheer R. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93(11):3798–802.
Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–5.
Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T, European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.
Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995;16(2):271–5.
Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant. 2010;45(4):699–704.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ciszewski, A., DeLoughery, T. (2013). Bleeding and Thrombosis in Hematologic Neoplasia. In: Wiernik, P., Goldman, J., Dutcher, J., Kyle, R. (eds) Neoplastic Diseases of the Blood. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3764-2_61
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3764-2_61
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3763-5
Online ISBN: 978-1-4614-3764-2
eBook Packages: MedicineMedicine (R0)